{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T08:24:38Z","timestamp":1750062278274,"version":"3.40.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.humimm.2024.111089","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T18:53:35Z","timestamp":1724352815000},"page":"111089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The clinical importance of IFN-\u03b3 and human epididymis protein 4 in Egyptian patients with epithelial ovarian cancer combined with HPV infection"],"prefix":"10.1016","volume":"85","author":[{"given":"Nourhan E.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasra F.","family":"Abdel Fattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed G.","family":"Seadawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Lymona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah S.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa A.","family":"El Leithy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma M.","family":"Abdelwahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-9281","authenticated-orcid":false,"given":"Auhood","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.111089_b0005","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s10096-021-04282-7","article-title":"Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis","volume":"40","author":"Cherif","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2020","key":"10.1016\/j.humimm.2024.111089_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2024","key":"10.1016\/j.humimm.2024.111089_b0015","first-page":"229","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humimm.2024.111089_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/437971","article-title":"Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.humimm.2024.111089_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx443","article-title":"Real-world evidence in the treatment of ovarian cancer","volume":"28","author":"Eisenhauer","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.humimm.2024.111089_b0030","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.humimm.2024.111089_b0035","doi-asserted-by":"crossref","unstructured":"R. Brett M., P. Jennifer B., S. Thomas A., R. Brett M., P. Jennifer B., S. Thomas A., Epidemiology of ovarian cancer: a review, Cancer Biol Med 14 (2017) 9\u201332. DOI: 10.20892\/j.issn.2095-3941.2016.0084.","DOI":"10.20892\/j.issn.2095-3941.2016.0084"},{"key":"10.1016\/j.humimm.2024.111089_b0040","first-page":"437","article-title":"The Prevalence of Human Papillomavirus in Ovarian Cancer: A Systematic Review, International Journal of Gynecologic","volume":"23","author":"Rosa","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.humimm.2024.111089_b0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41579-021-00617-5","article-title":"Human papillomaviruses: diversity, infection and host interactions","volume":"20","author":"McBride","year":"2022","journal-title":"Nat Rev Microbiol"},{"issue":"2018","key":"10.1016\/j.humimm.2024.111089_b0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2020","key":"10.1016\/j.humimm.2024.111089_b0055","first-page":"e180","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.humimm.2024.111089_b0060","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41416-019-0602-7","article-title":"Human papillomavirus as a driver of head and neck cancers","volume":"122","author":"Sabatini","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humimm.2024.111089_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.105086","article-title":"Human papillomavirus and ovarian cancer (review of literature and meta-analysis)","volume":"95","author":"Ibragimova","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.humimm.2024.111089_b0070","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.178.5.3186","article-title":"TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 16","volume":"178","author":"Hasan","year":"2007","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.humimm.2024.111089_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2007\/24147","article-title":"Cytokine Release in HR-HPV(+) Women without and with Cervical Dysplasia (CIN II and III) or Carcinoma, Compared with HR-HPV(<math id=\u201cE1\u201d> <mrow> <mstyle mathvariant=\u201cbold\u201d> <mo>\u2212<\/mo> <\/mstyle> <\/mrow> <\/math>) Controls","volume":"2007","author":"Bais","year":"2007","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.humimm.2024.111089_b0080","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1128\/JCM.43.8.3932-3937.2005","article-title":"Association of Tumor Necrosis Factor a - 2 and a - 8 Microsatellite Alleles with Human Papillomavirus and Squamous Intraepithelial Lesions among Women in Brazil","volume":"43","author":"Sim\u00f5es","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.humimm.2024.111089_b0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/CDLI.8.2.209-220.2001","article-title":"Cell-Mediated Immune Response to Human Papillomavirus Infection","volume":"8","author":"Scott","year":"2001","journal-title":"Clinical Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.humimm.2024.111089_b0090","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/biomedicines10112965","article-title":"Alteration of the IFN-Pathway by Human Papillomavirus Proteins: Antiviral Immune Response Evasion Mechanism","volume":"10","author":"Castro-Mu\u00f1oz","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.humimm.2024.111089_b0095","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/1541-7786.MCR-12-0353","article-title":"Revisiting the Complexity of the Ovarian Cancer Microenvironment\u2014Clinical Implications for Treatment Strategies","volume":"10","author":"Musrap","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.humimm.2024.111089_b0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.31557\/APJCP.2021.22.2.315","article-title":"Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis","volume":"22","author":"Fahmi","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.humimm.2024.111089_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1087620","article-title":"The role of interferons in ovarian cancer progression: Hinderer or promoter?","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.humimm.2024.111089_b0110","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2147\/IDR.S313219","article-title":"Presence of HPV, EBV and HMTV Viruses Among Egyptian Breast Cancer Women: Molecular Detection and Clinical Relevance","volume":"14","author":"Metwally","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"2021","key":"10.1016\/j.humimm.2024.111089_b0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.humimm.2024.111089_b0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","article-title":"Potential clinical utility of liquid biopsies in ovarian cancer","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer"},{"issue":"75","key":"10.1016\/j.humimm.2024.111089_b0125","first-page":"e1","article-title":"Pelvic inflammatory disease and risk of epithelial ovarian cancer: a national population-based case-control study in Sweden","volume":"230","author":"Jonsson","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.humimm.2024.111089_b0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12957-024-03336-2","article-title":"Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer","volume":"22","author":"Jia","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0140","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0145","series-title":"Cochrane Database of Systematic Reviews","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2009"},{"key":"10.1016\/j.humimm.2024.111089_b0150","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2024.111089_b0160","doi-asserted-by":"crossref","first-page":"12619","DOI":"10.1007\/s13277-016-5166-z","article-title":"A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC\u2013IV ovarian cancer\u2014a part of the Danish prospective pelvic mass study","volume":"37","author":"Karlsen","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.humimm.2024.111089_b0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13027-016-0087-4","article-title":"High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population","volume":"11","author":"Ingerslev","year":"2016","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.humimm.2024.111089_b0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-9378-7-35","article-title":"The role of infectious agents in urogenital cancers","volume":"7","author":"Alibek","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.humimm.2024.111089_b0175","doi-asserted-by":"crossref","unstructured":"A.-B. Moscicki, M. Schiffman, S. Kjaer, L.L. Villa, Chapter 5: Updating the natural history of HPV and anogenital cancer, Vaccine 24 (2006) S42\u2013S51. DOI: 10.1016\/j.vaccine.2006.06.018.","DOI":"10.1016\/j.vaccine.2006.06.018"},{"key":"10.1016\/j.humimm.2024.111089_b0180","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(10)70017-6","article-title":"HPV-associated head and neck cancer: a virus-related cancer epidemic","volume":"11","author":"Marur","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0185","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10096-012-1570-5","article-title":"Viral and bacterial aetiologies of epithelial ovarian cancer","volume":"31","author":"Shanmughapriya","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.humimm.2024.111089_b0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/1743-422X-10-343","article-title":"Human papillomavirus genotyping and integration in ovarian cancer Saudi patients","volume":"10","author":"Al-Shabanah","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.humimm.2024.111089_b0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1447-0756.2006.00376.x","article-title":"Analysis of ovarian tumors for the presence of human papillomavirus DNA","volume":"32","author":"Quirk","year":"2006","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"71","key":"10.1016\/j.humimm.2024.111089_b0200","first-page":"e1","article-title":"Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions","volume":"202","author":"Idahl","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.humimm.2024.111089_b0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/aogs.12254","article-title":"Prevalence of human papillomavirus in epithelial ovarian cancer tissue","volume":"93","author":"Svahn","year":"2014","journal-title":"A Meta-Analysis of Observational Studies, Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.humimm.2024.111089_b0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.humimm.2024.111089_b0215","first-page":"4495","article-title":"Effects of endometrial cancer complicated with HPV infection on HE4 and Th1\/Th2 cytokines","author":"Zhao","year":"2020","journal-title":"Int. J. Clin. Exp. Med"},{"key":"10.1016\/j.humimm.2024.111089_b0220","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1530\/ror.0.0030086","article-title":"Molecular characterization of epididymal proteins","volume":"3","author":"Kirchhoff","year":"1998","journal-title":"Rev Reprod"},{"key":"10.1016\/j.humimm.2024.111089_b0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbrc.2005.05.125","article-title":"The evolution of a genetic locus encoding small serine proteinase inhibitors","volume":"333","author":"Clauss","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humimm.2024.111089_b0230","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0235","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jog.13181","article-title":"Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer","volume":"43","author":"Lee","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"228","key":"10.1016\/j.humimm.2024.111089_b0240","first-page":"e1","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.humimm.2024.111089_b0245","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2016.01.016","article-title":"HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study","volume":"141","author":"Romagnolo","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000446238","article-title":"Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?","volume":"82","author":"Yanaranop","year":"2017","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.humimm.2024.111089_b0255","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","article-title":"The role of novel biomarker HE4 in endometrial cancer: a case control prospective study","volume":"34","author":"Angioli","year":"2013","journal-title":"Tumor Biol."},{"key":"10.1016\/j.humimm.2024.111089_b0260","first-page":"256","article-title":"The importance of HE4 in differential diagnosis of endometrial cancer","volume":"80","author":"Min\u00e1\u0159","year":"2015","journal-title":"Ceska Gynekol"},{"key":"10.1016\/j.humimm.2024.111089_b0265","doi-asserted-by":"crossref","first-page":"20180571","DOI":"10.1259\/bjr.20180571","article-title":"Low-grade epithelial ovarian cancer: what a radiologist should know","volume":"92","author":"Elsherif","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.humimm.2024.111089_b0270","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humimm.2024.111089_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00526","article-title":"The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway","volume":"11","author":"Martin-Hijano","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.humimm.2024.111089_b0280","first-page":"32","article-title":"Interferon-\u03b3 signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer, NPJ Precis","volume":"3","author":"Cardenas","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.humimm.2024.111089_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109412","article-title":"Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING","volume":"36","author":"Bruand","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.humimm.2024.111089_b0290","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41467-017-00729-8","article-title":"Bacterial outer membrane vesicles suppress tumor by interferon-\u03b3-mediated antitumor response","volume":"8","author":"Kim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.humimm.2024.111089_b0295","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.humimm.2024.111089_b0300","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00262-011-1128-x","article-title":"Immunotherapy with IL-10- and IFN-\u03b3-producing CD4 effector cells modulate \u201cNatural\u201d and \u201cInducible\u201d CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer","volume":"61","author":"Dobrzanski","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.humimm.2024.111089_b0305","doi-asserted-by":"crossref","first-page":"9531","DOI":"10.3390\/ijms22179531","article-title":"TNF-\u03b1 and IFN-\u03b3 Participate in Improving the Immunoregulatory Capacity of Mesenchymal Stem\/Stromal Cells: Importance of Cell-Cell Contact and Extracellular Vesicles","volume":"22","author":"L\u00f3pez-Garc\u00eda","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924003495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924003495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:38:21Z","timestamp":1726220301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924003495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0198885924003495"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111089","relation":{},"ISSN":["0198-8859"],"issn-type":[{"type":"print","value":"0198-8859"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical importance of IFN-\u03b3 and human epididymis protein 4 in Egyptian patients with epithelial ovarian cancer combined with HPV infection","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111089"}}